Lapatinib

Kinase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Lapatinib is an ofp drug in the Kinase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2007. Its mechanism of action is classified as Protein Kinase Inhibitors. DrugCentral lists 22 molecular targets, including EGFR, ERBB2 and ERBB4. Recorded indications include HER2-positive carcinoma of breast.

• Approval status: ofp (first approved 2007 by the FDA).
• Drug class: Kinase Inhibitor.
• Mechanism of action: Protein Kinase Inhibitors.
• Molecular targets: EGFR, ERBB2, ERBB4 and Tuba1a (22 listed in DrugCentral).
• Indications: HER2-positive carcinoma of breast.
• ATC code: L01EH01 (Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors).
• Molecular formula: C29H26ClFN4O4S; molecular weight 581.07 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• HER2-positive carcinoma of breast

Contraindications (13)

• Breastfeeding (mother)
• Congenital long QT syndrome
• Drug-induced hepatitis
• Hepatic failure
• Hypokalemia
• Hypomagnesemia
• Interstitial pneumonia
• Left heart failure
• Liver function tests abnormal
• Pregnancy, function
• Prolonged QT interval
• Severe diarrhea
• Torsades de pointes

Mechanism & targets

• Mechanism of action (MoA): Protein Kinase Inhibitors
• Established pharmacologic class: Kinase Inhibitor

Molecular targets (22)

Target	Gene	Action	Activity
Epidermal growth factor receptor	EGFR	inhibitor	Kd 9.04
Receptor tyrosine-protein kinase erbB-2	ERBB2	inhibitor	Kd 8.15
Receptor tyrosine-protein kinase erbB-4	ERBB4	unknown	Kd 7.27
Tubulin alpha-1A chain	Tuba1a	unknown	Kd 7.27
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	PIK3C2B	unknown	Kd 6.17
Phosphatidylinositol 4-kinase beta	PI4KB	unknown	Kd 6.03
Dual specificity mitogen-activated protein kinase kinase 5	MAP2K5	unknown	Kd 5.96
Serine/threonine-protein kinase 10	STK10	unknown	Kd 5.59
ATP-binding cassette sub-family G member 2	ABCG2	unknown	EC50 5.50
STE20-like serine/threonine-protein kinase	SLK	unknown	Kd 5.48
Proto-oncogene tyrosine-protein kinase Src	SRC	unknown	IC50 5.46
Receptor-interacting serine/threonine-protein kinase 2	RIPK2	unknown	Kd 5.44
Dual specificity mitogen-activated protein kinase kinase 7	MAP2K7	unknown	Kd 5.36
Receptor tyrosine-protein kinase erbB-3	ERBB3	unknown	Kd 5.26
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma	PIK3C2G	unknown	Kd 5.12
Platelet-derived growth factor receptor beta	PDGFRB	unknown	IC50 5.07
Cyclin-dependent kinase 2	CDK2	unknown	IC50 4.96
Insulin receptor	INSR	agonist	IC50 4.77
Tyrosine-protein kinase ABL1	ABL1	unknown	IC50 4.64
Replicase polyprotein 1ab	REP	unknown	Ki 4.64

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2008-06-10	EMA	—	—
2007-03-13	FDA	—	NOVARTIS PHARMS CORP

ATC classification

ATC code	Therapeutic hierarchy
L01EH01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: ERBB2, ESR1, ESR2 · Testing Required
• EMA label: HLA-DQA1, HLA-DRB1 · Informative PGx
• FDA label: ERBB2, ESR1, ESR2, PGR · Testing Required
• FDA label: HLA-DQA1, HLA-DRB1 · Informative PGx
• HCSC label: HLA-DQA1, HLA-DRB1 · Informative PGx
• HCSC label: ERBB2 · Testing Required
• PMDA label: ERBB2, HLA-DQA1, HLA-DRB1 · Testing Required
• Swissmedic label: HLA-DQA1, HLA-DRB1 · Actionable PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Palmar-plantar erythrodysaesthesia syndrome	2140.7
Diarrhoea	1757.1
Metastases to central nervous system	1063.6
Disease progression	1055.7
Malignant neoplasm progression	492.8
Paronychia	447.9
Metastases to lung	372.6
Neutropenia	357.3
Metastases to liver	354.7
Metastases to lymph nodes	328.3
Breast cancer metastatic	310.7
Dehydration	308.3

Chemical structure

• Molecular formula: C₂₉H₂₆ClFN₄O₄S
• Molecular weight: 581.07 g/mol
• CAS number: —
• InChIKey: BCFGMOOMADDAQU-UHFFFAOYSA-N
• PubChem CID: 208908

CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)C2=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Lapatinib used for?

DrugCentral lists the following indications for Lapatinib: HER2-positive carcinoma of breast.

How does Lapatinib work?

Lapatinib is classified as Protein Kinase Inhibitors; its molecular targets in DrugCentral include EGFR (inhibitor), ERBB2 (inhibitor), ERBB4 and Tuba1a.

When was Lapatinib first approved?

Lapatinib was first approved by the FDA in 2007.

What drug class does Lapatinib belong to?

Lapatinib is in the Kinase Inhibitor class.

What is the chemical formula of Lapatinib?

Lapatinib has the molecular formula C29H26ClFN4O4S and a molecular weight of 581.07 g/mol.

Sources

• DrugCentral drug card 1548 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201179 — compound record and bioactivity
• PubChem CID 208908 — chemical identifiers
• DrugBank DB01259 — drug record
• FDA UNII 0VUA21238F — substance identity
• DailyMed: FDA labels for Lapatinib — current prescribing information (label search)
• UniProt P00533 (EGFR) — target protein
• UniProt P04626 (ERBB2) — target protein
• UniProt Q15303 (ERBB4) — target protein
• UniProt O00750 (PIK3C2B) — target protein
• UniProt Q9UBF8 (PI4KB) — target protein
• UniProt Q13163 (MAP2K5) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.